(Alliance News) - GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases ...
Shares of GSK PLC GSK inched down 0.34% to £16.04 Wednesday, on what proved to be an all-around rough trading session for the ...
LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...
LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...
GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...
London stocks were set to jump at the open on Tuesday following a flat close in the previous session, as investors eyed the ...
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback